Why do we need new treatments for rheumatoid arthritis?

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 4, 1998, Pages 357-369

  Chikanza, I C ^a   Jawed, S ^a   Naughton, D ^a   Blake, D R ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOMALATE; COLLAGEN; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; OM 89; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HOST RESISTANCE; HUMAN; HYPOXEMIA; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATORY DISEASE; JOINT DEGENERATION; META ANALYSIS; NONHUMAN; PLEIOTROPY; REMISSION; RHEUMATOID ARTHRITIS;

EID: 0031970199     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb06874.x     Document Type: Conference Paper

References (84)

1. Akira, S., Hirano, T., Taga, T., Kishimoto, I. (1990) Biology of multi-functional cytokines: IL-6 and related molecules (IL-1 and TNF). Fed. Am. Soc. Exp. Biol. J. 4: 2860-2867
2. Anggard, E. (1994) Nitric oxide: mediator, murderer and medicine. Lancet 343: 1199-1206
3. Arend, W. P., Dayer, J. M. (1990) Cytokines and cytokines inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33: 305-315
4. Arend, W. P., Dayer, J. M. (1995) Inhibition of the production and effects of interleukin-1 and tumour necrosis alpha in rheumatoid arthritis. Arthritis Rheum. 38: 151-160
5. Arend, W. P., Malyak, M., Smith, M. F., Whisenend, T. D., Slack, J. L., Sims, J. E., Giri, J. G., Dower, S. K. (1994) Binding of IL-1α , IL-1β and IL-1Ra by soluble IL-1 receptors and levels of soluble IL-1 receptors by synovial fluid. J. Immunol. 153: 4766-4774
6. Bandara, G., Mueller, G. M., Galea-Lauri, J., Tindal, M. H., Georgescu, H. I., Suchaneek, M. K., Hung, G. H. L., Glorioso, J. C., Robbins, P. D., Evans, G. H. (1993) Intra-articular expression of biologically active interleukin-1 receptor antagonist protein by ex-vivo gene transfer. Proc. Natl Acad. Sci. USA 90: 10764-10768
7. Beavo, J. A., Reisfeld, D. H. (1990) Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11: 150-161
8. Besedovsky, H., del Roy, A., Sorkin, E., Dinarello, C. (1986) Immunoregulatory feedback between IL-1 and the glucocorticoid hormones. Science 233: 652-666
9. Blake, D. R., Naughton, D. P., Adams, G. E., Stratford, I. J., Morris, C. J., Jaffar, M., Naylor, M. (1997) GB Patent Application No. 11.66215/000
10. Boers, M., Tugwell, P., Felston, D. T., et al (1994) WHO and IL-R core end points for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J. Rheumatol. 21: 86-89
11. Brackertz, D., Vischer, T. L. (1989) OM-8980 in rheumatoid arthritis: a six month, double blind placebo controlled study. J. Rheumatol. 16: 19-23
12. Brennan, F. M., Chantry, D., Jackson, A., Maini, R. N., Feldmann, M. (1989) Inhibitory effects of TNFα antibodies on synovial cell IL-1 production in RA. Lancet ii: 244-247
13. Bresnihan, B., et al (1996) Treatment of with recombinant human IL-1Ra: results of a randomised double blind, placebo-controlled study. Arthritis. Rheum. 39: S73
14. Carmichael, D. F., Stricklin, G. P., Stuart, J. M. (1989) Systemic administration of TIMP in the treatment of collagen induced arthritis in mice. Agents Action 27: 378-379
15. Chikanza, I. C., Roux-Lombard, P., Dayer, J-M., Panayi, G. S. (1995) Dysregulated interleukin-1 receptor antagonist protein production in rheumatoid arthritis; pathogenetic implications. Arthritis Rheum. 38: 642-648
16. Chikanza, I. C. (1996) The neuroendocrine immunology of rheumatoid arthritis. Bailliere's Clinical Rheumatology 10: 273-293
17. Chikanza, I. C., Grossman, A. S. (1996) Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop. Bailliere's Clinical Rheumatology 10: 199-225
18. Chikanza, I. C., Jawed, S., Blake, D. R., Perrot, S., Menkes, S., Barnes, C. G., Perry, J. D., Wright, M. G. (1996) Treatment of patients with RA with RP73401 phosphodiesterase type 4 inhibitor. Arthritis Rheum. 39: S282
19. Clark, S. D., Kobayashi, D. K., Welgus, H. G. (1987) Regulation of the expression of TIMP and collagenase by retinoids and glucocorticoids in human fibroblasts. J. Clin. Invest 890: 1280-1288
20. Colotta, F., Re F., Muzio, M. (1993) Interleukin-1 type receptor: A decoy target for IL-1 that is regulated by IL-4. Science 261: 472-475
21. Drevlow, B. E., Lovis, R., Haag, M. A., Sinacore, J. M., Bloshe, C., Landay, A., Moreland, L. W., Pope, R. M. (1996) Recombinant human interleukin-1 receptor type 1 in the treatment of patients with active RA. Arthritis Rheum. 39: 257-265
22. Edmonds, S. E., Blake, D. R., Morris, C. J., Winyard, P. G. (1993) An imaginative approach to synovitis - the role of hypoxic reperfusion damage in arthritis. J. Rheum. 20: 26-31
23. Elliot, M. J., Maini, R. N., Feldman, M., Kalden, J. R., Antoni, C., Smolen, J., Leeb, B., Breedveld, E. C., MacFarlane, J. D., Bijl, H., Woody, J. N. (1994a) Randomised double blind comparison of chimaeric antibody to TNFα (cA2) in patients with rheumatoid arthritis. Lancet 344: 1105-1110
24. Elliot, M. J., Maini, R. N., Feldman, M., Long-Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., Woody, J. N. (1993) Treatment of rheumatoid arthritis with chimaeric mAb to TNFα. Arthritis Rheum. 36: 1681-1690
25. Elliot, M., Maini, R., Feldman, M., Long-Fox, A., Charles, P., Bijl, H., Woody, J. N. (1994b) Repeated therapy with mAb to TNFα (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125-1127
26. Felston, D., Anderson, J., Meenan, R. (1994) The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 37: 1487-1499
27. Firestein, G. S. (1996) Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum. 39: 1781-1790
28. Firestein, G., Boyle, D. L., Yu, C., Paine, M. M., Whisenand, T. D., Zvaifler, N. J., Arend, W. P. (1994) Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 37: 644-652
29. Gearing, A. J. H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M., Wooley, K. (1994) Processing of tumor necrosis factor alpha precursors by metalloproteinase. Nature 370: 555-557
30. Greenwald, R. A., Golub, L. M., Lavietes, B., Ramamurthy. N. S., Gruber, B., Laskin, R. S., McNamara, T. F. (1987) Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J. Rheumatol. 14: 28-32
31. Hanamaijer, R., Koolwijk, P., Le Clercq, L. (1993) Regulation of metalloproteinase expression in human vein and microvascular endothelial cells. Biochem. J. 296: 803-809
32. Harding, M. W., Ku, G., Faust, T., Lauffer, L. L., Livingstone, D. (1995) Interleukin-1β converting enzyme inhibition blocks progression of type 2 collagen induced arthritis in mice. Arthritis Rheum. 38: S400
33. Hartman, J. W., Davidson, B. L., Roessler, F. J. (1993) Genetic modification of synoviocytes in vivo using recombinant adenoviral vectors (abstract). Arthritis Rheum. 36: S64
34. Hasler, F., van de Putte, L., Baudin, M., Ludin, E., Durrwell, L., McAuliffe, T., Van der Auwera, P. (1996) Chronic TNFα neutralisation upto 1 year by lenercept in patients with RA: results of an open label extension of a double blind single dose phase 1 study. Arthritis Rheum. 39: S243
35. Hauzeur, J. P., Applebom, T. (1989) Double-blind placebo controlled study of OM-8980 in RA. Rheumatol. Int. 9: 71-76
36. Herzyk, D. J., Berger, A. E., Allen, J. N., Werner, M. D. (1992) Sandwich ELISA formats designed to detect 17kDa IL-1β significantly underestimates 35kDa IL-1β. J. Immunol. Methods 148: 243-254
37. Isomaki, P., Luukkanes, R., Saario, R., Toivaren, P., Punnonen, J. (1996) IL-10 functions as an anti-inflammatory cytokine in rheumatoid arthritis. Arthritis Rheum. 39: 386-395
38. Joosten, L. A. B., Helsen, M. A., van den Berg, W. B. (1995) Effect of IL-10 on murine SCW arthritis: role of TNF and IL-1 in joint inflammation and cartilage destruction. Arthritis Rheum. 38: S401
39. Joosten, L. A. B., Helsen, M. M. A., van de Loo, F. A. J., van de Berg, W. B. (1996) Anticytokine treatment of established type 2 collagen induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1β/α and IL-1Ra. Arthritis Rheum. 39: 797-809
40. Kavanaugh, A. F., Davis, L. S., Nichols, L. A., Norris, S. H., Rothlein, R., Scharschmidt, L. A., Lipsky, P. (1994a) Treatment of refractory rheumatoid arthritis with monoclonal antibody to ICAM-1. Arthritis Rheum. 37: 992-999
41. Kavanaugh, A., Davis, L., Nichols, L., Lipsky, P. (1994b) Retreatment of RA patients with an anti-ICAM-1 monoclonal antibody. Arthritis Rheum. 38: S280
42. Kavanaugh, A., Rita, J., McFarlin, J., Nichols, L., Lipsky, P. (1994c) Anti-Cd54 (ICAM-1) monoclonal antibody therapy in early RA. Arthritis Rheum. 37: S220
43. Khoury, S. J., Akalin, E., Chandraker, A., Turka, L. A., Linsley, P., Sayegh, M. H., Hancock, W. W. (1995) CD28-B7 costimulatory blockade by CTLA-4IgG prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155: 4521-4524
44. Kim, K. U., Kwon O. J., Jue D. M. (1993) Pro-tumour necrosis factor cleavage factor enzyme in macrophages membrane particulate. Immunol. 83: 134-139
45. Kloppenburg, M., Breeveld, F. C., Terwiel, J. P., Mallee, C., Dijkmans, B. A. C. (1994) Minocycline in active RA: a double blind placebo-controlled trial. Arthritis Rheum. 37: 629-636
46. Knoerzer, D. B., Karr, R. W., Schwartz, B. D., Mengle-Gaw, L. J. (1995) Collagen induced arthritis in the BB rat; prevention of disease by treatment with CTLA-4Ig. J. Clin. Invest. 96: 987-993
47. Kuhlmann, F., Rohlig, C., Lukoschek, M., Lemmel, E. M., Heilig, B. (1994) Effects of IL-10 on synovial fluid mononuclear cells of patients with rheumatic diseases. Arthritis Rheum. 37: S309
48. Lebsack, M. E., Paul, C. C., Martindale, J. J., Catalano, M. A. (1993) A dose and regimen ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis (abstract). Arthritis Rheum. 36: S39
49. Lebsack, M. E., Paul, C. C., Bloedow, D. C., Burch, F. X., Sack, M. A., Chase, W., Catalano, M. A. (1991) Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 34: S45
50. Linsley, P. S., Greene, J. L., Tan, P., Bradshaw, J., Ledbetter, J. A., Anasette, C., Damle, N. K. (1992a) Co-expression and functional co-operation of CTLA4 and CD28 on activated lymphocytes. J. Exp. Med. 176: 1595-1604
51. Linsley, P. S., Ledbetter, J. A. (1993) The role of CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11: 191-212
52. Linsley, P. S., Wallace, P. M., Johnson, J., Gibson, M. G., Greene, J. L., Ledbetter, J. A., Singh, C., Tepper, M. A. (1992b) Immunosuppression in vivo by a soluble form of CTLA-4 T cell activation molecule. Science 257: 792-795
53. Mackay, C. R., Imhof, B. A. (1993) Cell adhesion in the immune system. Immunology Today 14: 99-102
54. Maksymowych, W. P., Avina-Zubieta, A., Luong, M. H., Russel, A. S. (1995) An open study of pentoxyfylline in the treatment of severe refractory RA. J. Rheumatol. 22: 625-629
55. Malaise, M. G., Ribbens, C., Kaye, O., Fontaine, M., Beckers, C., Mahieu, P. (1994) A synovial soluble TNF-receptor (60 and 80kDa) level imbalance reflects erosive disease in RA. Arthritis Rheum. 37: S193
56. Moreland, L. W., Margolies, G. R., Heck, L. W., Saway, P. A., Beck, C., Blosch, C., Hanna, R., Koopman, W. J. (1996) Recombinant soluble tumour necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory RA. J. Rheumatol. 23: 1849-1855
57. O'Dell, J. R., Haire, C. E., Palmer, W., Drymalski, W., Wees, S., Blakeley, K., Churchill, M., Eckhoff, P. J., Weaver, A., Doud, S., Eriksson, N., Dietz, F., Olson, R., Maloley, P., Klassen, L. W., Moore, G. F. (1997) Treatment of early RA with minocycline or placebo: results of a double blind placebo controlled trial. Arthritis Rheum. 40: 842-848
58. Paleolog, E. M., Taylor, P. C., Hunt, M., Tak, P. P., Elliott, M. J., Feldman, M., Breedveld, F. C., Maini, R. N. (1995) Treatment of rheumatoid arthritis with antibody to TNFα decreases expression of and sheding of E-selectin. Arthritis Rheum. 38: S279
59. Pincus, T. (1992) The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin. Arthritis Rheum. 21: 2-15
60. Pope, R. M., Drevlow, B. E., Capezio, J., Lovis, R., Jacobs, C., Bloshe, C., Beck, C., Haag, M. A., Landay, A. (1997) Intra-articular administration of recombinant human IL-1 receptor type 1 in patients with active RA. In: Biologic Agents in Autoimmune Disease IV (In press)
61. Pybus, P. K. (1964) Metronidazole and rheumatoid arthritis. S. A. Med. J. 65: 454
62. Rankin, E. C. C., Choy, E. H. S., Ehrenstein, M. R., Ravirajan, C. T., Sopwith, M., Vetterlein, O., Panayi, G. S., Isenberg, D. A. (1994) A double blind, placebo ascending dose trial of the recombinant humanised anti-TNFα anti-body CDP571 in patients with RA. Arthritis Rheum. 37: S295
63. Rankin, E. C. C., Choy, E. H. S., Ehrenstein, M. R., Ravirajan, C. T., Sopwith, M., Vetterlein, O., Panayi, G. S., Isenberg, D. A. (1995) Serological effects of repeated doses of an engineered anti-TNFα mAb, CDP571 in patients with RA. Arthritis Rheum. 38: S279
64. Roessler, F. J., Allen, E. D., Wilson, J. M., Hartman, J. W., Davidson, B. L. (1993) Adenoviral-mediated gene transfer to rabbit synovium in vivo. J. Clin. Invest. 92: 1085-1092
65. Rosenthal, M., Plattner, S. (1981) The treatment of rheumatoid arthritis with OM-8980. J. Rheumatol. 40: 228-231
66. Sadouk, M., Pelletier, J. P., Tardif, K., Kiansa, K., Cloutier, J. M., Martel-Pelletier, J. (1994) Coexpression of IL-1R1 and IL-1R2 in human OA synovial fibroblasts: binding and biological activity is mediated exclusively by type 1 receptor. Arthritis Rheum. 37: S306
67. Sander, O., Rau, R., Riel, P., van der Putte, L., Hasler, F., Baudin, M., Ludin, E., McAuliffe, T., Dickinson, S., Kahny, M., Lesslauer, W., Van der Auwera, P. (1996) Neutralisation of TNFα by lenercept (TNFsRSS-IgG1, RO-45-2081) in patients with RA treated for 3 months. Arthritis Rheum. 39: S242
68. Santos, L. L., Morad, E. F., Holdsworth, S. R. (1995) Suppression of adjuvant arthritis by n-iminoethyl-1-ornithine, a nitric oxide synthase inhibitor. Arthritis Rheum. 38: S371
69. Seckinger, P., Vey, E., Turcatti, G., Wingfield, P., Dayer, J. M. (1990) TNF inhibitor: purification, NH2 terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities. Eur. J. Immunol. 20: 1167-1174
70. Semmler, J. H., Wachtel, H., Endres, S. (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses TNFα production by human mononuclear cells. Int. J. Immunopharmacol. 15: 409-418
71. Sieper, J., Kary, S., Sorenson, H., Alten, R., Eggens, U., Huge, W., Hiepe, F., Kuhne, A., Listing, J., Ulbrich, N., Braun, J., Zink, A., Mitchison, N. A. (1996) Oral type 2 collagen treatment in early RA. A double-blind placebo-controlled, randomised study. Arthritis Rheum. 39: 41-51
72. Sommer, N., Loschmann, P. A., Northoff, G. H., Weller, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Riethmuller, A., Fontana, A., Dichgans, J., Martin, R. (1995) The anti-depressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1: 244-248
73. Staines, N. A., Harper, N., Bevan, D. J., Thompson, H. S. G. (1992) Oral tolerance: potential therapy for autoimmune diseases. 8ème Symposium International d'Immunorheumatologie, Montpellier, pp 239-250
74. Stevens, C. R., Blake, D. R., Merry, P., Revell, P. A., Levick, J. R. (1991) A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum. 34: 1508-1513
75. Suttorp, N., Weber, U., Welsch, T., Schudt, C. (1993) Role of phosphodiesterase in the regulation of endothelial permeability in vitro. J. Clin. Invest. 91: 1421-1426
76. Svenson, M., Hansen, M. B., Heegard, P., Abell, K., Bendtzen, K. (1993) Specific binding of IL-1 and IL-1Ra to human serum: high affinity binding of IL-1Ra to soluble IL-1 receptor type 1. Cytokine. 5: 421-435
77. Thiel, M., Bardenheuer, H., Poch, G., Madel, C., Peter, K. (1991) Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. Biochem. Biophys. Res. Commun. 180: 53-58
78. Tilley, B. C., Alarcon, G. S., Heyse, J. C., Trentham, D. E., Neuner, R., Kaplan, D. A., Clegg, D. O., Leisen, J. C., Buckley, L., Cooper, S. M. (1995) Minocycline in RA: a 48 week, double blind placebo controlled trial. Ann. Int. Med. 122: 81-89
79. Trentham, D. R., Dynesius-Trentham, R. A., Orav, E. J., Combitchi, D., Lorenzo, C., Sewell, K. L., Hafler, D. A., Weiner, H. L. (1993) Effects of oral administration of type 2 collagen on rheumatoid arthritis. Science 261: 1727-1730
80. Verstraenten, A., Sileghem, A., Dequeker, J. (1990) OM-8980 and d-penicillamine in the treatment of rheumatoid arthritis: a 12 months double randomised blind study. Scand. J. Rheumatol. 19: 422-431
81. Vischer, T. (1988) A double blind multicentre study of OM-8980 and auranofin in RA. Ann. Rheum. Dis. 47: 582-587
82. Williams, R. O., Mason, L. M., Feldman, M., Maini, R. (1994) Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen induced arthritis. Proc. Natl Acad. Sci. USA 91: 2762-2766
83. Wilson, K. P., Black, J-A. F., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A., Murcko, M. A., Chambers, S. P., Aldape, R. A., Raybuck, S. A., Livingston, D. J. (1994) Structure and mechanism of action of interleukin-1β converting enzyme. Nature 370: 270-275
84. Wolfe, F., Hawley, D. J., Cathey, M. A. (1991) Clinical and health status measures over time - prognosis and outcome assessment in RA. J. Rheumatol. 18: 1290-1297